Press release
Global Biomarkers Market Set to Surpass USD 104 Billion by 2030 as Precision Medicine and Drug Development Accelerate
The global Biomarkers Market is gaining strong strategic momentum as pharmaceutical, biotechnology, and healthcare stakeholders increasingly rely on biomarker-driven insights to improve drug development success, diagnostic accuracy, and personalized treatment strategies. According to the latest industry analysis, the biomarkers market is expected to grow from USD 62.39 billion in 2025 to USD 104.15 billion by 2030, registering a robust compound annual growth rate (CAGR) of 10.8% during the forecast period.
This growth highlights how biomarkers have moved from exploratory research tools to mission-critical assets that inform regulatory decisions, clinical trial design, and real-world patient management.
Download PDF Brochure:- https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=43 [https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=43&utm_source=abnewswire.com&utm_medium=referral&utm_campaign=paidpr]
Market Scope and Structure
The report titled "Biomarkers Market by Offering (Consumables, Software, Services), Type (Safety, Efficacy), Research Area (Genomics, Proteomics), Technology (PCR, MS), Disease (Cancer, Infectious, Neurological), Application (Diagnostic, Research) - Global Forecast to 2030" provides an in-depth evaluation of the market. It features 706 market data tables and 56 figures across 559 pages, offering comprehensive insights into technology trends, disease applications, and regional adoption patterns.
The market's expansion is primarily driven by the increasing use of biomarkers in drug discovery and development, where they enable early target identification, patient stratification, and optimized clinical trial design. Why does this matter now? As R&D costs rise and regulatory scrutiny intensifies, biomarkers help reduce late-stage failures and accelerate time-to-market.
Why Biomarkers Are Critical to Healthcare and Life Sciences Today
What is fueling biomarker adoption globally? The growing importance of companion diagnostics, particularly in oncology, is linking biomarker data directly to treatment decisions. The rising global burden of cancer is further driving demand for early detection, predictive, and prognostic biomarkers that support timely and effective interventions.
At the same time, the shift toward personalized medicine and precision oncology is increasing the need for biomarkers that guide individualized treatment plans. Collaboration among pharmaceutical companies, diagnostic developers, and healthcare providers-especially in emerging economies with expanding healthcare infrastructure-is accelerating biomarker integration across research and clinical workflows.
However, challenges remain. Complex biomarker validation requirements, quantification hurdles, and the integration of large, multi-omic datasets continue to limit broader adoption, underscoring the need for standardized platforms and regulatory alignment.
Consumables Lead the Market by Offering
By offering, consumables accounted for the largest share of the biomarkers market in 2024. This segment includes assay kits, reagents & chemicals, and columns & filters, all of which are essential for routine biomarker research, diagnostics, and validation workflows.
The dominance of consumables reflects their recurring demand and high usage frequency across laboratories and clinical settings. The increasing number of biomarker-based studies and clinical trials has further intensified demand for reliable, high-throughput consumables that ensure reproducibility and scalability. Additionally, the growing adoption of multiplex assay platforms, which require specialized consumables to detect multiple biomarkers from limited sample volumes, continues to support this segment's leadership.
Safety Biomarkers Dominate by Type
By type, safety biomarkers held the largest market share in 2024. These biomarkers play a critical role in assessing toxicity and identifying potential adverse effects early in the drug development process.
Why are safety biomarkers so important now? Regulatory agencies increasingly require robust safety biomarker data before drug candidates advance to later-stage clinical trials. In response, pharmaceutical companies are investing heavily in safety biomarker strategies to de-risk pipelines, reduce late-stage failures, and improve decision-making during preclinical and early clinical development.
PCR Emerges as the Fastest-Growing Technology
By technology, the PCR segment is expected to register the highest growth rate from 2025 to 2030. PCR's high sensitivity, cost-effectiveness, and broad applicability in detecting and quantifying nucleic acid-based biomarkers make it a preferred platform across diagnostic and research applications.
How are companies responding? Many are expanding PCR-based test portfolios, developing multiplex PCR kits, and integrating PCR platforms into companion diagnostics. While PCR is leading growth, complementary technologies such as NGS and mass spectrometry (MS) remain critical for comprehensive biomarker analysis, particularly for high-throughput sequencing and protein-level insights.
North America Maintains Market Leadership
Regionally, North America accounted for the largest share of the biomarkers market in 2024. This leadership is supported by a strong healthcare and research infrastructure, high R&D spending, and the presence of major pharmaceutical and biotechnology companies.
The region benefits from high adoption of advanced technologies, including next-generation sequencing and companion diagnostics, favorable regulatory frameworks, and substantial funding from both public and private sources. The rising prevalence of chronic diseases-particularly cancer and cardiovascular conditions-continues to sustain demand for biomarker-based diagnostics and therapies across North America.
Request For Sample Pages:- https://www.marketsandmarkets.com/requestsampleNew.asp?id=43 [https://www.marketsandmarkets.com/requestsampleNew.asp?id=43&utm_source=abnewswire.com&utm_medium=referral&utm_campaign=paidpr]
Competitive Landscape
The biomarkers market features a mix of global leaders and innovative challengers. Key players include F. Hoffmann-La Roche Ltd (Switzerland), Merck KGaA (Germany), Thermo Fisher Scientific Inc. (US), Abbott (US), QIAGEN (Netherlands), Revvity (US), Laboratory Corporation of America Holdings (US), Charles River Laboratories (US), Bio-Rad Laboratories, Inc. (US), Eurofins Scientific (Luxembourg), BIOMERIEUX (France), Agilent Technologies, Inc. (US), and JSR Corporation (Japan), along with numerous competitive startups and SMEs.
Strategic Implications for Decision-Makers
For CEOs, R&D leaders, and healthcare strategists, biomarkers represent a strategic foundation for precision medicine, efficient drug development, and data-driven clinical decisions. As regulatory expectations and patient complexity increase, investments in robust biomarker platforms will be critical to maintaining competitive advantage.
Media Contact
Company Name: MarketsandMarkets Trademark Research Private Ltd.
Contact Person: Mr. Rohan Salgarkar
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=global-biomarkers-market-set-to-surpass-usd-104-billion-by-2030-as-precision-medicine-and-drug-development-accelerate]
Phone: 18886006441
Address:1615 South Congress Ave. Suite 103, Delray Beach, FL 33445
City: Florida
State: Florida
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/biomarkers-advanced-technologies-and-global-market-43.html
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Global Biomarkers Market Set to Surpass USD 104 Billion by 2030 as Precision Medicine and Drug Development Accelerate here
News-ID: 4380968 • Views: …
More Releases from ABNewswire
Rett Syndrome Clinical Trial Pipeline Appears Robust With 20+ Key Pharma Compani …
DelveInsight's, "Rett Syndrome Pipeline Insight 2026" report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Rett Syndrome pipeline landscape. It covers the Rett Syndrome pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Rett Syndrome pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Curious about the latest updates in…
Chronic Rhinosinusitis with Nasal Polyps Clinical Trial Pipeline Expands as 8+ C …
DelveInsight's "Chronic Rhinosinusitis with Nasal Polyps Pipeline Insight 2026" report provides comprehensive insights about 8+ companies and 10+ pipeline drugs in the Chronic Rhinosinusitis with Nasal Polyps pipeline landscape. It covers the Chronic Rhinosinusitis with Nasal Polyps Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Chronic Rhinosinusitis with Nasal Polyps Pipeline Therapeutics assessment by product type, stage, route of administration, and molecule type. It further…
Stargardt Disease Treatment Pipeline Shows Strong Momentum as 20+ Pharma Compani …
DelveInsight's "Stargardt Disease Pipeline Insight 2026" report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in the Stargardt Disease pipeline landscape. It covers the Stargardt Disease pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Curious about the latest updates in the Stargardt…
Heart Failure Clinical Trial Pipeline Appears Robust With 70+ Key Pharma Compani …
DelveInsight's, "Heart Failure Pipeline Insight 2026" report provides comprehensive insights about 70+ companies and 75+ pipeline drugs in Heart Failure pipeline landscape. It covers the Heart Failure pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Heart Failure pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight…
More Releases for PCR
Emerging Trends to Reshape the Global Real-Time PCR, Digital PCR And End-Point P …
Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Real-Time PCR, Digital PCR And End-Point PCR Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
The market encompassing real-time PCR, digital PCR, and end-point PCR has experienced robust expansion over the past few years, projecting a rise from $38.37 billion in 2024 to $41.55 billion…
Role Of Real-Time Rt-Pcr In Accelerating Covid-19 Diagnosis And Driving Pcr And …
The PCR And Realtime PCR Testing Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Current PCR And Realtime PCR Testing Market Size and Its Estimated Growth Rate?
The PCR and real-time PCR testing market has grown strongly, rising from $10.55 billion in 2024…
Role Of Real-Time Rt-Pcr In Accelerating Covid-19 Diagnosis And Driving Pcr And …
How Will the PCR And Realtime PCR Testing Market Grow, and What Is the Projected Market Size?
There has been a significant growth in the market size of PCR and realtime PCR testing in the last few years. Its size is expected to increase from $10.55 billion in 2024 to $11.21 billion in 2025, with a Compound Annual Growth Rate (CAGR) of 6.3%. The growth observed in the historic period is…
Role Of Real-Time Rt-Pcr In Accelerating Covid-19 Diagnosis And Driving Pcr And …
How Will the PCR And Realtime PCR Testing Market Grow, and What Is the Projected Market Size?
There has been a significant growth in the market size of PCR and realtime PCR testing in the last few years. Its size is expected to increase from $10.55 billion in 2024 to $11.21 billion in 2025, with a Compound Annual Growth Rate (CAGR) of 6.3%. The growth observed in the historic period is…
Q-PCR and D-PCR Devices Market: Revolutionizing Molecular Diagnostics
The Q-PCR and D-PCR devices market has experienced significant growth in recent years, driven by advancements in molecular biology and the increasing demand for accurate and sensitive diagnostic tools. These technologies have revolutionized the field of molecular diagnostics, enabling researchers and clinicians to detect and quantify specific DNA or RNA sequences with high precision.
Market Size and Growth
The global Q-PCR and D-PCR devices market is estimated to be worth billions of…
Real-Time PCR, Digital PCR And End-Point PCR Global Market Analysis, Trends, Gro …
The new report published by The Business Research Company, titled "Real-Time PCR, Digital PCR And End-Point PCR Global Market Report 2024 - Market Size, Trends, And Global Forecast 2024-2033", delivers an in-depth analysis of the leading size and forecasts, investment opportunities, winning strategies, market drivers and trends, competitive landscape, and evolving market trends.
As per the report, the real-time pcr, digital pcr and end-point pcr market size has grown strongly…
